Moderate to Severe Plaque Psoriasis: Clinical Trials

9 trials for Moderate to Severe Plaque Psoriasis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 2 not yet recruiting, 1 active not recruiting. 9 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 29Completed 6, Not yet recruiting 2, Active not recruiting 1
Phase 31Not yet recruiting 1

Follow Moderate to Severe Plaque Psoriasis: new trials by email Literature Review of Moderate to Severe Plaque Psoriasis trials Research Report on Moderate to Severe Plaque Psoriasis

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque Psoriasis
HS-20118, Placebo - Moderate to Severe Plaque Psoriasis
Phase 2Not yet recruitingJiangsu Hansoh Pharmaceutical Co., Ltd.1202026-08-062026-08-14
A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis
CMS-D001 50mg, CMS-D001 100mg, Placebo - Moderate to Severe Plaque Psoriasis
Phase 2 / Phase 3Not yet recruitingDermavon Holdings Limited5402026-03-032026-02-25
A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis
SHR-1139 Injection, SHR-1139 Injection Placebo - Moderate to Severe Plaque Psoriasis
Phase 2Active not recruitingGuangdong Hengrui Pharmaceutical Co., Ltd1452025-03-282025-07-14
Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis
ICP-488 Tablets, ICP-488 Placebo - Moderate to Severe Plaque Psoriasis
Phase 2CompletedBeijing InnoCare Pharma Tech Co., Ltd.1292024-01-042025-02-28
Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis
NDI-034858 study drug, Placebo - Moderate to Severe Plaque Psoriasis
Phase 2CompletedTakeda2592021-08-112023-09-28
A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
bimekizumab - Moderate to Severe Plaque Psoriasis
Phase 2CompletedUCB Biopharma SRL412021-04-062026-08-03
To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis
Placebo, SCD-044_Low Dose (Dose 1), SCD-044_Intermediate Dose (Dose 2) - Moderate to Severe Plaque Psoriasis
Phase 2CompletedSun Pharmaceutical Industries Limited2632021-03-252026-01-20
A Phase 2 Clinical Study of KHK4827
KHK4827, Placebo - Moderate to Severe Plaque Psoriasis
Phase 2CompletedKyowa Kirin Co., Ltd.1402012-12-012013-09-05
Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis
IMO-3100 at 0.16 mg/kg, Saline for Injection, IMO-3100 at 0.32 mg/kg - Actively Extending Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Phase 2CompletedIdera Pharmaceuticals, Inc.442012-05-012018-01-09

Narrower conditions

Psoriasis (2)

Broader conditions

Skin Diseases (2)  ·  Skin Diseases, Papulosquamous (2)  ·  Skin and Connective Tissue Diseases (2)

Interventions

Injections (1)  ·  Sodium Chloride (1)  ·  bimekizumab (1)  ·  brodalumab (1)

Sponsors

Beijing InnoCare Pharma Tech Co., Ltd. (1)  ·  Dermavon Holdings Limited (1)  ·  Guangdong Hengrui Pharmaceutical Co., Ltd (1)  ·  Idera Pharmaceuticals, Inc. (1)  ·  Jiangsu Hansoh Pharmaceutical Co., Ltd. (1)  ·  Kyowa Kirin Co., Ltd. (1)  ·  Sun Pharmaceutical Industries Limited (1)  ·  Takeda (1)  ·  UCB Biopharma SRL (1)

Countries

United States (4)  ·  China (3)  ·  Canada (2)  ·  Poland (2)  ·  El Salvador (1)  ·  Estonia (1)  ·  Georgia (1)  ·  Germany (1)  ·  Japan (1)

Top investigators

Robert D Arbeit, MD (1)

Results publications

PMID 26547109, PMID 39167366, PMID 42143206

NIH funding

2023 (1)